Irritable Bowel Syndrome

Paradowski, Leszek

doi:10.1007/978-981-19-0120-1_16

Cited by 1 publication

(1 citation statement)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBS is known to be more prevalent in females and lowers their quality of life more frequently than in males. 42 Considering the higher psychological distress experienced by the general female IBS population, 5 it was noteworthy to observe higher QoL score changes reported by the females in our study. We assume that the potential role of multi-strain probiotics in modulating gut microbiota may be different according to sex.…”

Section: Discussionmentioning

confidence: 45%

Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study

Chang,

Choi,

Shin

et al. 2024

J Neurogastroenterol Motil

Self Cite

View full text Add to dashboard Cite

Background/Aims To evaluate the efficacy of quadruple-coated probiotics (gQlab) in patients with irritable bowel syndrome (IBS), focusing on sex differences and IBS subtypes. Methods One hundred and nine Rome III-diagnosed IBS patients were randomized into either a gQlab or placebo group and received either gQlab or a placebo for 4 weeks. Participants replied to questionnaires assessing compliance, symptoms, and safety. Fecal samples were collected at 0 and 4 weeks to measure the probiotic levels using real-time quantitative polymerase chain reaction (qPCR) and to perform metagenomic analysis via 16S ribosomal DNA sequencing. The primary endpoint was the change in the overall IBS symptoms after 4 weeks of treatment. Results Ninety-two subjects (47 and 45 in the gQlab and placebo groups, respectively) completed the study protocol. At week 4, there was a higher relief of the overall IBS symptoms in the gQlab group ( P = 0.005). The overall IBS symptom improvement was statistically significant ( P = 0.017) in female patients of the gQlab group compared with the placebo group. Among the IBS subtypes, constipation-predominant IBS patients showed significant relief of the overall IBS symptoms ( P = 0.002). At week 4, the fecal microbiome profiles between the 2 groups did not differ, but the qPCR levels of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus helveticus, Bifidobacterium longum, and Bifidobacterium breve were increased in the gQlab group ( P < 0.05 by repeated measures ANOVA). Conclusions gQlab administration can improve the overall IBS symptoms, especially in female and constipation-predominant IBS patients. Further research is necessary to clarify the pathophysiology behind sex-related treatment responses in IBS patients.

show abstract

Section: Discussionmentioning

confidence: 45%